call
mani
biolog
version
swiss
armi
knive
proteas
cut
long
sequenc
amino
acid
fragment
regul
physiolog
process
vital
import
life
cycl
becom
main
target
drug
design
chapter
focus
special
proteas
play
key
role
replic
sar
sever
acut
respiratori
syndrom
coronaviru
culprit
sar
diseas
progress
report
mainli
variou
comput
approach
structur
bioinformat
pharmacophor
model
kc
chou
et
al
molecular
dock
peptidecleavag
site
predict
among
other
highlight
compound
c
h
n
cl
c
h
n
c
h
n
well
deriv
might
promis
candid
investig
octapeptid
atlqaia
atlqaenv
well
avlqsgfr
might
convert
effect
inhibitor
sar
proteas
meanwhil
modifi
octapeptid
base
distort
key
theori
make
becom
potent
inhibitor
explicitli
elucid
also
brief
introduct
given
use
computergener
graph
rapidli
diagnos
sar
coronaviru
final
stepbystep
protocol
guid
given
use
protid
webserv
develop
recent
identifi
proteas
type
base
sequenc
inform
alon
protid
userfriendli
bioinformat
tool
provid
desir
inform
basic
research
drug
discoveri
time
manner
avalanch
protein
sequenc
gener
postgenom
age
particularli
use
protid
freeli
access
public
via
websit
proteas
also
term
proteinas
peptidas
enzym
essenti
stage
life
cycl
concept
birth
growth
age
death
organ
function
biolog
version
swiss
armi
knive
cleav
long
sequenc
amino
acid
fragment
process
indispens
synthesi
protein
control
protein
composit
size
shape
turnov
ultim
destruct
therefor
help
us
better
understand
biolog
life
treatment
diseas
studi
proteas
receptor
inhibitor
respiratori
ill
call
sever
acut
respiratori
syndrom
sar
first
report
asia
novemb
ill
spread
two
dozen
countri
north
america
south
america
europ
asia
within
month
patient
suffer
sar
usual
begin
high
fever
symptom
headach
malais
chilli
rigor
diarrhoea
bodi
ach
follow
develop
dri
nonproduct
cough
troubl
breath
might
accompani
progress
hypoxia
condit
insuffici
oxygen
reach
bodi
tissu
patient
develop
pneumonia
fatal
rate
around
known
culprit
caus
sar
sar
coronaviru
sometim
shorten
sarscov
peiri
et
al
also
known
key
step
replic
culprit
cleav
sarscoronaviru
polyprotein
special
proteas
socal
sar
coronaviru
main
proteas
sar
cov
mpro
function
import
proteas
viral
life
cycl
made
attract
target
develop
drug
sar
conduct
ration
structurebas
drug
design
key
step
understand
bind
interact
sar
cov
mpro
ligand
progress
synthesi
novel
test
compound
antivir
chemotherapi
sar
summar
kesel
kesel
drug
discoveri
sarscov
report
recent
review
chapter
focu
progress
mainli
approach
computeraid
drug
discoveri
base
atom
coordin
sarscov
mpro
anand
et
al
two
bind
model
develop
chou
et
al
one
bind
interact
sarscov
mpro
compound
call
fig
octapeptid
avlqsgfr
chou
et
al
permiss
chou
et
al
deriv
fig
latter
develop
pfizer
inc
current
clinic
trial
treatment
rhinoviru
pathogen
caus
common
cold
shown
fig
pfluorophenylalanin
side
chain
pfluorobenzyl
long
bulki
fit
bind
pocket
sarscov
mpro
remov
side
chain
compound
thu
obtain
could
well
fit
bind
pocket
shown
fig
constitu
bind
pocketar
defin
residu
least
one
heavi
atom
ie
hydrogen
distanc
heavi
atom
similar
bindingpocket
defin
atp
atp
complex
chou
et
al
studi
see
eg
troy
b
chou
wei
et
wang
et
al
b
li
et
al
b
gu
et
al
gong
et
al
bind
pocket
sarscov
mpro
involv
residu
ligand
tether
enzym
six
hydrogen
bond
detail
chou
et
al
seri
followup
discuss
bind
mechan
found
zhang
yap
same
clercq
bind
interact
sarscov
mpro
octapeptid
avlqsgfr
illustr
fig
see
octapeptid
tether
sarscov
mpro
six
hydrogen
bond
bind
interact
mode
import
implic
stimul
ration
design
drug
sar
therapi
due
follow
consider
proteasesuscept
site
protein
usual
extend
octapeptid
gener
formul
p
p
p
p
p
p
p
p
scissil
bond
locat
subsit
p
p
gener
express
schechter
berger
miller
et
al
chou
sar
coronaviru
enzym
sever
viral
proteinas
exhibit
ser
ala
gli
specif
anand
et
al
accord
lockandkey
mechan
enzymolog
octapeptid
cleavabl
sar
proteas
must
good
fit
bind
activ
site
howev
peptid
modif
scissil
bond
simpl
routin
procedur
complet
lose
cleavabl
still
bind
activ
site
actual
molecul
thu
modifi
compar
distort
key
chou
insert
lock
neither
open
lock
pull
spontan
becom
ideal
competit
inhibitor
sar
proteinas
stimul
bind
interact
mode
seri
followup
studi
conduct
describ
mention
octapeptid
avlqsgfr
tether
sarscov
mpro
six
hydrogen
bond
instruct
point
analyz
hydrogen
bond
interact
receptor
ligand
often
provid
overal
view
complex
obtain
dock
octapeptid
avlqsgfr
sarscoronaviru
main
proteinas
octapeptid
colour
white
ballandstick
draw
sar
enzym
ribbon
draw
shown
figur
octapeptid
insert
cleft
domain
ii
expect
reproduc
chou
et
al
permiss
use
insight
drug
develop
see
eg
chou
chou
b
chou
howe
wei
et
al
wei
et
al
wei
et
al
b
wang
et
al
wang
et
al
b
c
li
et
al
chou
et
al
chou
et
al
du
et
al
du
et
al
du
et
al
zhang
et
al
gao
et
al
li
l
et
al
zheng
et
al
guo
et
al
schnell
et
al
base
hydrogen
bond
interact
sarscov
mpro
chou
et
al
templat
pharmacophor
point
gener
shown
fig
four
hydrogen
bond
acceptor
colour
cyan
two
hydrogen
bond
donor
purpl
aromat
group
green
volum
constrain
grey
base
pharmacophor
templat
virtual
screen
search
oper
perform
siroi
cowork
commerci
academ
avail
compound
found
pharmacophor
search
million
compound
screen
score
satisfi
five
six
pharmacophor
point
defin
four
hydrogen
bond
acceptor
two
hydrogen
bond
donor
fig
moreov
hit
compound
evalu
drugabl
accord
novel
score
function
equat
formul
metric
took
account
physic
lipinski
chemic
structur
properti
xu
stevenson
well
presenc
undesir
function
group
oprea
rishton
select
properti
base
work
propos
baurin
baurin
drugabilityevalu
procedur
found
compound
thu
retriev
first
hit
screen
perfect
score
one
violat
drugabl
rule
two
violat
two
violat
criterion
drugabl
set
maximum
allow
two
violat
obtain
fig
templat
pharmacophor
point
deriv
bind
interact
sarscov
pro
chou
et
al
four
hb
donor
color
cyan
two
hb
donor
purpl
aromat
group
green
volum
constrain
grey
reproduc
siroi
et
al
permiss
total
compound
screen
worthi
test
activ
find
would
significantli
narrow
search
scope
potenti
compound
save
substanti
time
money
final
featur
templat
deriv
pharmacophor
studi
would
also
use
guid
design
synthesi
effect
drug
sar
therapi
instruct
point
instead
choos
hydrogen
bond
donor
acceptor
pharmacophor
model
done
one
also
choos
featur
model
aromat
ring
hydrophob
aromat
hydrophob
aliphat
posit
charg
neg
charg
hydrogen
bond
acceptor
lipid
posit
ioniz
neg
ioniz
uniqu
hit
volum
constrain
found
siroi
et
al
drugabl
compound
collect
wei
cowork
match
dimension
pharmacophor
point
satisfi
drugabl
rule
score
valu
found
via
similar
search
auto
dock
oper
three
compound
ie
c
h
n
cl
c
h
n
c
h
n
promis
candid
worthi
investig
meanwhil
thermodynam
analysi
indic
hydrogen
bond
make
import
contribut
interact
sarscov
mpro
compound
quit
consist
case
chou
et
al
addit
hydrogen
bond
contribut
interact
desolv
hydrophob
interact
electrostat
interact
hydrogen
bond
may
play
role
anchor
determin
spatial
posit
compound
bind
pocket
thu
facilit
hydrophob
interact
electrostat
interact
therefor
conduct
ration
drug
design
critic
identifi
hydrophob
group
ligand
receptor
make
sure
face
upon
bind
also
observ
examin
connolli
surfac
connolli
complex
sarscov
mpro
three
compound
steric
complementar
respons
micromechan
interlock
molecular
level
word
steric
complementar
ligand
collagen
receptor
site
play
role
primari
drive
forc
mechan
interlock
main
featur
share
aforement
three
potenti
inhibitor
well
inform
involv
side
chain
sarscov
mpro
may
provid
use
insight
develop
potent
inhibitor
sar
enzym
recent
wang
et
al
perform
virtual
screen
find
natur
inhibitor
cathepsinl
sar
therapi
wang
et
al
owe
inabl
readili
cross
membran
barrier
intestin
bloodbrain
barrier
develop
peptid
drug
limit
poor
metabol
stabil
low
bioavail
howev
peptid
drug
low
toxic
human
bodi
organ
compound
henc
systemat
chemic
modif
strategi
convert
peptid
drug
attract
research
topic
current
medicin
chemistri
adessi
soto
effort
made
attempt
develop
peptid
inhibitor
sarscov
pro
chou
et
al
du
et
al
du
et
al
du
et
al
b
zhang
et
al
develop
peptid
inhibitor
proteas
base
distort
key
theori
chou
illustr
follow
accord
lockandkey
mechan
enzymolog
proteasecleav
peptid
must
satisfi
substrat
specif
ie
good
match
bind
activ
site
phrase
good
match
understood
broad
sens
rather
narrow
geometr
sens
ie
mean
favour
chemicalgroupdisposit
bind
substrat
activ
site
enzym
catalyt
reaction
thereof
howev
peptid
modif
scissil
bond
chemic
procedur
complet
lose
cleavabl
still
bind
activ
site
enzym
actual
molecul
thu
modifi
compar
distort
key
insert
lock
neither
open
lock
pull
molecul
modifi
cleavabl
peptid
spontan
becom
competit
inhibitor
enzym
illustr
use
concept
distort
key
find
peptid
inhibitor
sar
enzym
given
fig
panel
show
effect
bind
cleavabl
peptid
activ
site
sar
cov
pro
panel
b
show
peptid
becom
noncleav
one
scissil
bond
modifi
although
still
bind
activ
site
modifi
peptid
distort
key
automat
becom
inhibitor
candid
sar
cov
pro
instruct
point
even
case
develop
nonpeptid
inhibitor
knowledg
thu
acquir
also
provid
use
insight
key
bind
group
proper
microenviron
fit
conform
among
mani
subtl
requir
therefor
significantli
reduc
search
scope
expedit
process
find
desir
peptid
inhibitor
comput
method
avail
one
discern
kind
peptid
cleav
sar
cov
pro
process
develop
inhibitor
hiv
proteas
mani
algorithm
develop
chou
b
poorman
et
al
chou
et
al
chou
et
al
zhang
chou
thompson
et
al
cai
chou
et
al
liang
li
rognvaldsson
et
al
predict
cleavabl
peptid
hiv
proteas
recent
freeli
access
webserv
call
hivcleav
also
establish
identifi
cleavag
site
protein
hiv
proteas
stimul
distort
key
theori
find
peptid
inhibitor
hiv
proteas
similar
bioinformat
tool
also
develop
gao
et
al
chen
et
al
find
peptid
inhibitor
sarscov
pro
du
cowork
du
et
al
use
tool
search
sar
coronavirus
found
cleavag
site
cleavabl
octapeptid
extract
order
find
physic
chemic
properti
amino
acid
posit
r
r
du
et
al
align
cleavabl
peptid
use
flexibl
molecular
align
techniqu
result
given
fig
panel
show
lipophil
hydrophil
amino
acid
side
chain
cleavabl
peptid
panel
b
show
pharmacophor
type
atom
relev
amino
acid
side
chain
shown
figur
residu
r
r
lipophil
residu
r
r
partial
lipophil
residu
hand
residu
r
hydrophil
residu
r
r
partial
hydrophil
residu
residu
r
could
lipophil
hydrophil
size
side
chain
r
small
volum
side
chain
residu
r
r
r
larger
other
aromat
group
posit
r
r
subsequ
dock
oper
perform
cleavabl
peptid
respect
sar
cov
pro
found
cleavabl
peptid
nh
highest
affin
sar
cov
pro
fig
schemat
illustr
show
cleavabl
octapeptid
chemic
effect
bound
activ
site
sar
cov
mpro
b
although
still
bound
activ
site
peptid
lost
cleavabl
scissil
bond
modifi
strong
hybrid
peptid
bond
eight
residu
peptid
sequenti
symbol
r
r
r
r
r
r
r
r
counter
part
respect
adapt
chou
permiss
bind
interact
enzym
nh
obtain
dock
oper
shown
fig
although
cleavabl
peptid
fittingli
bind
activ
site
proteas
inhibitor
enzym
scissil
peptid
bond
eventu
cleav
howev
cleavabl
peptid
becom
effect
inhibitor
proper
chemic
modif
elabor
chou
convert
cleavabl
peptid
stabl
bioavail
drug
hot
research
topic
medicin
chemistri
chou
du
et
al
possibl
chemic
modif
method
regard
analyz
accord
distort
key
theori
chou
cleavabl
oligopeptid
automat
becom
competit
inhibitor
scissil
peptid
bond
r
r
replac
strong
hybrid
peptid
bond
cf
fig
case
nh
posit
r
r
occupi
amino
acid
gln
fig
align
cleavabl
peptid
hydrophil
hydrophob
surfac
peptid
green
lipophil
region
blue
hydrophil
region
b
atom
pharmacophor
type
peptid
atom
color
accord
pharmacophor
type
donor
white
acceptor
cyan
acceptor
donor
magenta
cation
reson
cation
light
blue
anion
reson
anion
red
hydrophob
dark
green
gray
atom
fig
bind
interact
obtain
dock
octapeptid
atlqaenv
sar
cov
pro
green
hydrophob
region
blue
hydrophil
region
cleavabl
peptid
shown
space
fill
model
bioactiv
pocket
cleavag
caviti
domain
ii
protom
ala
peptid
bond
co
nh
gln
ala
consid
pseudo
conjug
use
co
nh
emphas
conjug
easili
hydrolyz
sar
cov
pro
group
co
replac
ch
nh
replac
ch
conjug
becom
strong
singl
bond
henc
hydrolyz
becom
difficult
szelk
et
al
venkatesan
kim
gener
methylamino
isoster
prepar
reduct
amid
bond
differ
reduc
agent
reduct
amin
amino
aldehyd
benkiran
et
al
isoster
incorpor
ra
farnesylprotein
transferas
inhibitor
potenti
anticanc
drug
graham
et
al
pseudo
peptid
analog
contain
reduc
amid
isoster
also
shown
inhibit
c
nc
cleavag
gag
region
proteas
lowther
et
al
also
observ
quantum
chemistri
calcul
co
replac
ch
charg
carbon
atom
ch
turn
neg
origin
posit
valu
co
group
henc
nucleophil
attack
oh
becam
imposs
furthermor
neg
charg
n
nh
ser
side
decreas
henc
electrophil
attack
h
becam
difficult
well
hand
experi
gan
et
al
gan
et
al
indic
octapeptid
avlqsgfr
propos
origin
chou
et
al
inde
cleavabl
sarscov
pro
high
bioactiv
base
crystal
structur
sarscov
pro
yang
et
al
cleavag
mechan
sarscov
pro
octapeptid
nh
chou
et
al
investig
use
molecular
mechan
mm
quantum
mechan
qm
du
et
al
observ
catalyt
dyad
site
domain
ii
proteas
attract
densiti
peptid
bond
glnser
increas
posit
charg
c
co
gln
neg
charg
n
nh
ser
weaken
glnser
peptid
bond
catalyt
function
group
imidazol
group
n
imidazol
ring
play
acidbas
catalyt
role
also
found
chemic
bond
gln
ser
becom
much
stronger
longer
cleavabl
sar
enzym
either
chang
carbonyl
group
co
gln
ch
cf
chang
nh
ser
ch
cf
accord
distort
key
theori
chou
octapeptid
thu
modifi
might
becom
effect
inhibitor
sarscov
pro
potenti
drug
candid
sar
therapeut
analyz
twodimension
cellular
automata
imag
wolfram
wolfram
sar
coronaviru
nonsar
coronaviru
wang
et
al
wang
et
al
found
remark
distinct
sar
nonsar
coron
virus
imag
former
vshape
crosslin
pattern
fig
imag
latter
parallel
slashlin
pattern
fig
conclud
vshape
crosslin
imag
pattern
might
deem
fingerprint
sar
coron
virus
rapidli
diagnos
sar
coronaviru
subsequ
gao
cowork
gao
et
al
develop
anoth
graphic
method
visual
characterist
sarscov
merit
clear
visibl
reliabl
serv
complementari
clinic
tool
detect
sarscov
particularli
case
result
obtain
convent
method
uncertain
conflict
owe
indispens
role
life
cycl
proteas
becom
import
target
drug
discoveri
differ
type
proteas
differ
action
mechan
biolog
process
avalanch
new
protein
sequenc
gener
postgenom
age
highli
desir
develop
autom
method
time
identifi
proteas
type
accord
sequenc
inform
alon
recent
web
server
call
protid
proteas
identifi
establish
http
wwwcsbiosjtueducnbioinfproteas
protid
twolay
predictor
first
layer
identifi
queri
protein
proteas
nonproteas
proteas
process
automat
go
second
layer
identifi
among
follow
six
function
type
aspart
cystein
glutam
metallo
serin
threonin
success
expect
protid
identifi
protein
proteas
nonproteas
identifi
proteas
type
userfriendli
web
server
protid
freeli
access
public
let
us
provid
stepbystep
guid
use
protid
get
desir
result
step
open
web
page
http
wwwcsbiosjtueducnbioinfproteas
see
top
page
protid
predictor
comput
screen
shown
fig
click
read
see
brief
introduct
protiden
predictor
caveat
use
step
either
type
copi
past
queri
protein
sequenc
input
box
center
fig
input
sequenc
singlelett
amino
acid
code
shown
click
exampl
button
right
input
box
instanc
input
amino
acid
sar
coronaviru
main
proteas
unit
taken
greybox
underlin
segment
box
input
screen
look
like
screenshot
fig
fig
cellular
automata
imag
obtain
appli
modifi
rule
wolfram
wolfram
step
click
submit
button
see
queri
protein
proteas
belong
cystein
type
shown
output
screen
fig
input
amino
acid
full
length
sar
coronaviru
proteas
taken
box
predict
result
obtain
although
take
much
longer
time
input
sequenc
much
longer
step
click
citat
button
find
relev
paper
document
detail
develop
algorithm
protid
step
click
data
button
download
benchmark
dataset
use
train
test
protid
predictor
obtain
predict
result
expect
success
rate
either
entir
sequenc
queri
protein
entir
sequenc
main
proteas
use
input
sinc
outbreak
sar
novemb
southern
china
guangdong
provinc
consider
progress
made
develop
drug
sar
therapi
chapter
focus
advanc
achiev
mainli
structur
bioinformat
pharmacophor
model
molecular
dock
peptidecleavag
site
predict
comput
approach
indic
compound
c
h
n
cl
c
h
n
c
h
n
well
chou
et
al
deriv
might
promis
candid
investig
meanwhil
elucid
accord
distort
key
theori
octapeptid
atlqaenv
avlqsgfr
may
convert
effect
inhibitor
sar
enzym
also
modifi
octapeptid
make
becom
potent
inhibitor
suggest
final
steptostep
guid
use
protid
web
server
identifi
proteas
type
present
may
use
peopl
work
area
proteas
biolog
diseas
